Partner David Rosen was quoted in a Health Care on Bloomberg Law
article, “Critics Say Trump’s Drug Price Talk Empty without Actions
,” about the FDA approving a record number of generic drugs in 2017 amid speculation that President Trump doesn’t want to lower prescription drug prices.
Rosen said it’s encouraging that drug pricing and generic drugs are on Trump’s mind. He explained that generic drugs “can certainly hold down health-care costs” by giving people access to products that are high quality, therapeutically equivalent and lower cost, and that FDA Commissioner Scott Gottlieb is working to make generic drugs more accessible and to ensure applications are approved in a timely manner.